Synergistic Therapeutic Potential of Citrulline and Bicarbonate in Immuno-Oncology

Citrulline & Bicarbonate: Metabolic Reprogramming for Cancer Immunotherapy

Transforming the hostile tumor microenvironment to enhance immune checkpoint therapy

Key Research Findings

• pH Neutralization: Bicarbonate reverses tumor acidity, restoring T-cell function
• Ammonia Detoxification: Citrulline fuels the intrinsic T-cell urea cycle for waste clearance
• Synergistic Action: Combined therapy addresses two distinct axes of immune suppression
• Immunotherapy Enhancement: Metabolic preconditioning may maximize checkpoint inhibitor efficacy

The Metabolic Barrier

Co-administration of citrulline and bicarbonate remains unexplored but there's a strong theoretical foundation for the combined use of citrulline and bicarbonate, even without a single definitive co-administration study. Citrulline and bicarbonate tackle two distinct, yet critical, immunosuppressive features of the Tumor Microenvironment (TME). Bicarbonate is shown to neutralize the acidic TME, which is known to inhibit T-cell activation and glycolysis, thereby enhancing the efficacy of immunotherapies like anti-PD-1/CTLA-4. Separately, citrulline is implicated in the urea cycle within CD8+ T cells, where it plays a crucial role in ammonia detoxification. High ammonia levels in the TME are a newly identified driver of T-cell exhaustion and decreased survival. This suggests a powerful potential synergy: bicarbonate addresses TME acidity, while citrulline addresses TME ammonia toxicity, both aiming to reactivate anti-tumor T-cell responses. While immune checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4) have revolutionized cancer treatment, a substantial proportion of patients—often exceeding 60-70% in solid tumor indications—fail to derive durable clinical benefit. ICI's efficacy is often limited by the hostile metabolic environment within tumors. The tumor microenvironment (TME) is characterized by severe metabolic dysregulation—particularly extracellular acidosis and toxic ammonia accumulation—that paralyzes infiltrating immune cells.

The Core Problem

Checkpoint inhibitors release the "brakes" on T cells, but if T cells are metabolically paralyzed by an acidic, ammonia-laden environment, releasing those brakes provides limited benefit. The solution requires transforming the TME from a suppressive "metabolic desert" into a permissive environment for anti-tumor immunity.

The Two Metabolic Threats

1. Tumor Acidosis (The Warburg Effect)

Cancer cells act as "acid factories," using glycolysis even when oxygen is available. This creates a reversed pH gradient:

• Intracellular pH: Maintained at 7.4–7.7 (slightly alkaline)
• Extracellular pH: Drops to 6.5–6.9 (acidic)

This acidity is a functional shield that paralyzes T-cell cytotoxicity, impairs antibody function, and selects for aggressive cancer phenotypes.

2. Intratumoral Hyperammonemia

Ammonia accumulates in tumors due to intense glutaminolysis and amino acid catabolism. Recent research has identified ammonia as a potent T-cell toxin that:

• Induces T-cell exhaustion
• Disrupts mitochondrial function
• Triggers a distinct form of cell death
• Impairs memory T-cell development

The Two-Pronged Solution

Bicarbonate: Neutralizing the Acid Barrier

Sodium bicarbonate (NaHCO₃) is the body's primary pH buffer system. Systemic alkalization with oral bicarbonate has been shown to:

Restore T-Cell Function

Reverses proton-mediated anergy and improves cytotoxic activity

Enhance Antibody Efficacy

Improves pharmacokinetics of immunotherapeutic antibodies

Reduce Metastasis

pH neutralization inhibits acid-driven invasion pathways

Preclinical Evidence

In mouse melanoma models, oral bicarbonate water significantly improved response to anti-PD-1, anti-CTLA-4, and adoptive T-cell therapy. Tumor growth was reduced and infiltrating lymphocyte function was restored.

Citrulline: Fueling the T-Cell Detox System

Citrulline is a non-proteinogenic amino acid and urea cycle intermediate with unique immunological properties:

Why Citrulline Over Arginine?

• Bypasses hepatic clearance: Circulates freely without first-pass metabolism
• Superior arginine delivery: Raises plasma arginine more effectively than arginine itself
• Selectively usable: Requires ASS1, which T-cells keep and many tumors have silenced
• Fuels ammonia detoxification: Directly supports the T-cell intrinsic urea cycle

ASS1: the enzyme that makes citrulline selective

A correction to an earlier version of this page, which described citrulline as bypassing ASS1 deficiency. It does the opposite: citrulline depends on ASS1. The enzyme condenses citrulline with aspartate to make argininosuccinate, which the next step splits into arginine. A cell that has silenced ASS1 cannot convert citrulline into anything useful at all.

That dependence is the whole point. Many tumors silence ASS1 by promoter hypermethylation, because doing so frees cytosolic aspartate for CAD and de novo pyrimidine synthesis—faster proliferation, bought at the cost of arginine autonomy. T-cells retain ASS1. So in an ASS1-silenced tumor, supplied citrulline is a precursor only the immune compartment can use.

The selectivity is therefore conditional on that status, and it is worth stating as a condition rather than a property. Against an ASS1-competent tumor, citrulline feeds both compartments and the advantage disappears—and those tumors are separately known to resist checkpoint blockade through purine metabolism. ASS1 expression is measurable by immunohistochemistry and already guides patient selection for arginine-deprivation therapy, so this is testable; no citrulline study has yet stratified by it.

A eUREkA! moment: The *T-Cell* Urea Cycle

A landmark study revealed that CD8⁺ memory T cells express a complete, functional urea cycle—previously thought exclusive to the liver. CPS1 is upregulated in these cells through β-hydroxybutyrylation, mitochondrial arginase 2 cleaves arginine into urea and ornithine, and nitric oxide synthase converts arginine into NO and citrulline. The cycle serves to:

• Detoxify intracellular ammonia
• Generate arginine for proliferation
• Produce fumarate for energy metabolism
• Promote long-lived memory T-cell development

Source: Tang et al., Nature Immunology 24(1):162–173, 2023. Note that this study characterizes the endogenous cycles; it did not administer citrulline, combine with immunotherapy, or perform adoptive transfer. That supplementation drives these cycles harder is an extrapolation from it, not a finding of it.

The Synergy Hypothesis

Citrulline and bicarbonate are not merely additive—they are mechanistically synergistic:

The Biochemical Connection

The urea cycle enzyme Carbamoyl Phosphate Synthetase 1 (CPS1)—the gateway to ammonia detoxification—requires bicarbonate as an obligatory substrate. The reaction:

NH₃ + HCO₃⁻ + 2 ATP → Carbamoyl Phosphate + 2 ADP + Pi

This is what makes the pairing complementary rather than redundant. The two agents reach different steps and neither substitutes for the other: supplied citrulline enters downstream of the fixation reaction—CPS1 fixes ammonia into carbamoyl phosphate, OTC then combines that with ornithine to form citrulline—and therefore cannot drive CPS1 itself, while bicarbonate acts at the fixation step and does nothing for the regeneration arm.

Combining pH normalization with urea cycle substrate is thus a push at two separate points, not two pushes at one.

One qualification on the CPS1 argument

Bicarbonate is an obligatory substrate of CPS1, but obligatory is not the same as rate-limiting. Intracellular and mitochondrial bicarbonate is set largely by CO₂ and carbonic anhydrase, and is not usually in short supply; oral bicarbonate acts principally on extracellular pH, which is a long and unquantified causal chain to mitochondrial substrate availability.

The enzyme's actual regulated input is N-acetylglutamate (NAG), an obligatory allosteric activator without which CPS1 does not run at all. If the specific goal were to drive the ammonia-fixing step, the mechanistically direct agent would be carglumic acid, an approved NAG analogue used for hyperammonemia in NAGS deficiency and organic acidemias. Bicarbonate's case in this combination rests on relieving tumor acidosis—which has its own evidence base, summarized above—rather than on being the limiting substrate for CPS1.

And a counter-mechanism: pH cuts both ways on ammonia

Ammonia and ammonium interconvert with a pKa near 9.25, so raising pH shifts the balance toward NH₃—the uncharged, lipid-soluble form that crosses membranes freely. This is not a theoretical worry. Alkalemia is a recognized precipitant of hepatic encephalopathy for exactly this reason, and ammonia intoxication has been reported during the treatment of alkalosis in patients with normal liver function. Bicarbonate therefore has two opposing effects on the nitrogen problem: it relieves acidosis and supplies CPS1, but it also increases the diffusible fraction of ammonia. Which effect dominates in a tumor already carrying a nitrogen load is unknown, and it is the first thing a co-administration study would need to measure.

Practical Implementation

Safety Considerations

Bicarbonate: Generally well-tolerated. Monitor for sodium load (hypertension risk), metabolic alkalosis, and GI discomfort. Contraindicated in certain cardiac and renal conditions.

Citrulline: Excellent safety profile as a naturally occurring amino acid. May interact with PDE5 inhibitors and nitrates. Caution advised in patients with citrullinemia or urea cycle disorders.

Enhancing Citrulline + Bicarbonate

Shikonin

Shikonin directly inhibits Pyruvate Kinase M2 (PKM2), thereby reducing the *production* of lactic acid (the source of acidity). This complements Bicarbonate, which neutralizes the *existing* acid. Shikonin inhibits c-Myc expression, a key driver of glutaminolysis (the source of ammonia). Thus, Shikonin works to reduce the *generation* of both lactic acid and ammonia, while Citrulline and Bicarbonate maintain the necessary clearance pathways. This research report serves as a theoretical expansion and critical assessment of integrating Shikonin—a naphthoquinone derivative isolated from Lithospermum erythrorhizon—into this combinatorial regimen.

References & Further Reading

Nature Immunology (2023): Ammonia detoxification promotes CD8+ T cell memory development by urea and citrulline cycles — Tang et al., 24(1):162–173; published online December 2022.

Cell Mol Immunol. (2023): eUREkA! T cells answer nature’s call

Cancer Research (2016): Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy — Pilon-Thomas et al., 76(6):1381–1390. See also the published correction, PMID 28461565.

Cell Metabolism (2023): Microenvironmental ammonia enhances T cell exhaustion in colorectal cancer — Bell, Shah et al.; published online December 2022.

Nature (2015): Diversion of aspartate in ASS1-deficient tumours fosters de novo pyrimidine synthesis — Rabinovich et al. Why tumors silence ASS1, and what it costs them.

Nature Cancer (2020): Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors — Keshet et al. The other half of the marker: ASS1-high tumors resist checkpoint blockade.

Frontiers in Immunology (2017): Reconstitution of T Cell Proliferation under Arginine Limitation via Citrulline

Frontiers in Oncology (2022): Clinical review of alkalization therapy in cancer treatment

Cancer Research (2019): Tumor Microenvironment Acidity and T Cell Function

PMC Review (2025): Urea cycle dysregulation: a new frontier in cancer metabolism and immune evasion

ClinicalTrials.gov: NCT01350583 - Bicarbonate for Tumor Related Pain

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. The combination therapy discussed is based on preclinical research and theoretical mechanisms. Always consult with qualified healthcare providers before making any changes to cancer treatment protocols.

Last updated: November 2025